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Abstract
Microtubule-associated protein 2 (MAP2) belongs to the family of heat stable MAPs, which takes part in neuronal
morphogenesis, maintenance of cellular architecture and internal organization, cell division and cellular processes. To
obtain insight into the possible alteration and the role of MAP2 in transmissible spongiform encephalopathies (TSEs), the
MAP2 levels in the brain tissues of agent 263K-infected hamsters and human prion diseases were evaluated. Western blots
and IHC revealed that at the terminal stages of the diseases, MAP2 levels in the brain tissues of scrapie infected hamsters, a
patient with genetic Creutzfeldt-Jakob disease (G114V gCJD) and a patient with fatal familial insomnia (FFI) were almost
undetectable. The decline of MAP2 was closely related with prolonged incubation time. Exposure of SK-N-SH
neuroblastoma cell line to cytotoxic PrP106-126 peptide significantly down-regulated the cellular MAP2 level and
remarkably disrupted the microtubule structure, but did not alter the level of tubulin. Moreover, the levels of calpain, which
mediated the degradation of a broad of cytoskeletal proteins, were significantly increased in both PrP106-126 treated SK-N-
SH cells and brain tissues of 263K prion-infected hamsters. Our data indicate that the decline of MAP2 is a common
phenomenon in TSEs, which seems to occur at an early stage of incubation period. Markedly increased calpain level might
contribute to the reduction of MAP2.
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Introduction
Prion diseases, also known as transmissible spongiform enceph-
alopathies (TSEs), are a group of fatal neurodegenerative diseases
of central nervous system (CNS), including bovine spongiform
encephalopathy in cattle, scrapie in sheep and goat, chronic
wasting disease (CWD) in deer and elk, and Kuru, Creutzfeldt-
Jakob disease(CJD), fatal familial insomnia (FFI) and Gerstmann-
Stra ¨ussler-Scheinker (GSS) syndrome in humans [1,2]. They are
characterized by progressive neuronal degeneration, neuronal
vacuolation and gliosis and the misfolding of normal cellular prion
(PrP
C) into an abnormal form of scrapie prion (PrP
Sc) that
accumulates in CNS [3].
A synthetic peptide corresponding to the amino acid residues
106–126 of prion protein (PrP106–126) is able to induce apoptosis
in the primary rat hippocampal cultures [4] and various human
neuroblastoma cell lines [5], as well as mouse retinae [6]. Similar
to PrP
Sc, it forms amyloid fibrilar aggregates and to catalyzes the
conversion of PrP
C to an amyloidogenic form [7]. The similarities
between the synthetic PrP106–126 peptide and native PrP
Sc to
some extents make it a useful mimic in the research of prion and
prion diseases.
Microtubules are polarized structures and assemble from
heterodimers of a- and b-tubulin in a GTP-dependent fashion.
It plays a central role in cellular transport, structural integrity and
cellular architecture. The polymerization, stabilization, arrange-
ment of microtubules can be modulated by interactions with a
series of microtubule-associated proteins (MAPs)[8]. Microtubule-
associated protein 2 (MAP2) belongs to a family of heat stable
MAPs, which takes part in neuronal morphogenesis, maintaining
cellular architecture and internal organization, cell division and
cellular processes [9]. In mammalian brain, MAP2 isoforms have
been divided into high-molecular weight MAP2 (HMWMAP2)
and low-molecular weight MAP2 (LMWMAP2). HMWMAP2
consists of MAP2a (Mr. 280 kDa) and MAP2b (Mr. 270 kDa,) that
are specially expressed in neurons, while LMWMAP2 includes
MAP2c (Mr. 70 kDa) and MAP2d (Mr. 75 kDa) that are present in
glial cells [10]. It has been reported that in the brains of
Alzheimer’s diseases, the levels of MAP2 are usually decreased
[11,12]. Treatment of Ab1–42 on C57BL/6J mouse primary
cerebral neurons and human neuroblastoma cells induce a
reduction of MAP2 [13,14]. However, the situations and roles of
MAP2 in TSE pathogenesis remain unclear.
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30163Many previously studies have repeatedly identified that the
levels of tubulin decreased in CNS tissues of naturally occurred
or experimental human and animal TSEs [15,16,17]. Our
previous studies have demonstrated that the CJD-associated
PrPs can disrupt the cellular microtubule structure through
different pathways [18]. Recently, by screening the transcrip-
tional diversity in the brains of human prion diseases with a
commercial mRNA microarray, we found that the expression
level of MAP2 is obviously decreased (unpublished data). In this
study, we found that MAP2 proteins in the brain tissues of
scrapie agent 263K-infected rodents and human genetic prion
diseases were almost undetectable at the terminal stages. The
decline of MAP2 in the brains of agent 263K-infected hamsters
was closely related with prolonged incubation time. These
phenomena could be reproduced in a human neuroblastoma
cell line SK-N-SH exposed to the synthetic peptide PrP106–
126, revealing the decrease of MAP2 and disruption of
microtubule structures. Meanwhile, the levels of calpain, which
mediates the degradation of a broad of cytoskeletal proteins,
were significantly increased in both the brain tissues of scrapie
agent 263K-infected hamsters and PrP106–126 treated SK-N-
SH cells.
Materials and Methods
Ethics statement
Usages of human and animal specimens in this study were
approved by the Ethical Committee of National Institute for Viral
Disease Prevention and Control, China CDC under protocol
2009ZX10004-101. All signed informed consents have been
collected and stored by the China CJD Surveillance Centre. All
Chinese golden hamsters were maintained under clean grade.
Housing and experimental protocols were in accordance with the
Chinese Regulations for the Administration of Affairs Concerning
Experimental Animals.
Samples from scrapie-infected hamsters, human gCJD
and FFI patients
Four Chinese golden hamsters inoculated intracerebrally with
hamster-adapted scrapie agent 263K and three normal hamsters
were enrolled in this study. In addition, the brain samples of the
agent 263K-infected hamsters collected on the 20th, 40th, 60th
and 80th day post inoculation were included as well. The brains
were removed surgically, immediately dissected, then frozen and
stored at 280uC until use. The postmortem brains of a G114V
gCJD case (47 year-old woman) [19] and a FFI case (26 year-old
woman) [20] were also enrolled in this study, which were
diagnosed by the experts of Chinese National Surveillance
Network for CJD (CNSNC).
Preparation of brain tissue samples
Brain tissues from experimental hamsters and the regions of
thalamus, cingulated gyrus, frontal cortex, parietal cortex,
occipital cortex and temporal cortex of human prion diseases
were collected and washed with iced TBS (10 mM Tris HCl,
133 mM NaCl, pH 7.4). 10% (w/v) brain homogenates were
prepared based on the protocol described previously [21]. Briefly,
brain tissues were homogenized in lyses buffer (100 mM NaCl,
10 mM EDTA, 0.5% Nonidet P-40, 0.5% sodium deoxycholate,
10 mM Tris, pH 7.5) containing a mixture of protease inhibitors.
The tissue debris was removed with low speed centrifugation at
2000 g for 10 min and the supernatants were collected for further
study.
Western blots
Aliquots of brain homogenates and cell extracts were separated
on 6% or 12% SDS-PAGE and electronically transferred to NC
membrane. Membranes were blocked with 5% (w/v) non-fat milk
powder (NFMP) in 16Tris-buffered saline containing 0.1%
Tween 20 (NFMP-TBST) at room temperature (RT) for 1 h
and probed with various primary antibodies at 4uC overnight,
including 1:1000-diluted anti-MAP2 pAb (Cell Signaling), 1:2000-
diluted anti-a-tubulin mAb (Sigma), 1:1500-diluted anti-Calpain
S1 mAb (EPR3324,Abcam), 1:5000-diluted anti-PrP mAb (3F4,
Chemicon) and 1:2000-diluted anti-b-actin mAb (Santa Cruz),
respectively. After washing with TBST, blots were incubated with
1:5000-diluted horseradish peroxidase (HRP)-conjugated goat
anti-mouse IgG or anti-rabbit IgG(Santa Cruz) respectively at
RT for 1 h. Blots were developed using Enhanced ChemoLumi-
nescence system (ECL, Amersham Life Sciences, Buckingham-
shire, UK) and visualized on autoradiography films.
Immunohistochemical (IHC) assays
Paraffin sections (5 mm in thickness) were prepared and
immunohistochemistry were performed according to the previous
protocol. Briefly, sections were quenched for endogenous peroxi-
dases in 3% H2O2 in methanol for 10 min, pretreated with enzyme
digestion antigen retrieval for 1 min. After blocked in 1% normal
goat serum, the sections were incubated with 1:100-diluted mAb for
MAP2, 1:1000-diluted mAb for PrP or 1:500-diluted mAb for
GFAP (Santa Cruz) at 4uC overnight, respectively. Subsequently,
the sections were incubated with 1:250-diluted HRP-conjugated
goat anti-mouse secondary antibody (Vector Labs, USA) for
60 min, and visualized by incubation with 3,39-diaminobenzidine
tetrahydrochloride (DAB). Finally, the slices were counterstained
with hematoxylin, then mounted in Permount.
Peptides and chemicals
PrP106-126 (KTNMKHMAGAAAAGAVVGGLG) and
scrambled PrP106-126 (SCR) (AVHTGLGAMAALNMVVG-
GAAGL) were synthesized and purified by Sheng Gong Biological
Co (Shanghai, China). The peptides were dissolved in DMSO at a
concentration of 50 mM and stored at 280uC.
Cell treatment and cell viability assays
Human SK-N-SH cells were obtained from Experimental
Animal Center of Sun Yat-sen University. Cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM, Gibco) that
contained 10% FBS (Gibco) in a humidified incubator supplied
with 5% CO2. SK-N-SH cells were seeded on a 96-well plate at a
concentration of 10
4 cells per well and cultured for 24 h. PrP106-
126 and SCR were diluted to the desired concentration in DMEM
without FBS and added directly to the cells. Cell viability was
determined by a commercially Cell Counting Kit (CCK-8,
Dojindo, Japan). 10 ml of CCK-8 regent were added to each well
and incubated at 37uC for 1 h, until the media turned yellow.
Each experiment was performed in triplicate and repeated at least
three times with separated cell preparations.
Immunocytochemical staining
Cells were fixed with formaldehyde (4% paraformaldehyde,
freshly depolymerized in 0.1 M sodium phosphate buffer, pH7.4)
at RT for 15 min and washed three times in PBS. After blocked
with blocking buffer (PBS with 5% FBS and 0.1% Trition X-100)
at RT for 1 h, cells were incubated with 1:50 diluted anti-MAP2
pAb (Cell Signaling) or 1:200 diluted anti-a-tubulin mAb (Sigma)
in dilute solution (PBS with 2% BSA and 0.3% Trition X-100) at
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diluted (v/v) appropriate secondary antibodies (Alexa Fluor anti-
mouse 488 or Alexa Fluor anti-rabbit 568, Invitrogen) in dilute
solution at RT for another 2 h. After washing, cells were
incubated with 0.5 mg/ml DAPI (Invitrogen) at RT for 2 min.
Cells were sealed and the images of the targeting proteins were
analyzed by microscope (Olympus BX51) and confocal microsco-
py (Leica ST2, Germany). Density analysis was performed using
Image-Pro Plus 5.0, and the mean optical density (MOD) was
slope value measured by counting the optical and area values of
each positive stained cell in a certain field of view.
Statistical analyses
Quantitative analysis of immunoblot images was carried out
using software Image J. The values of each target blot were
evaluated. All data are presented as the mean 6 SD. Statistical
analysis was performed using the T test. Probabilities of less than
0.05 were considered to be statistically significant.
Results
Decrease of MAP2 in the brains of 263K prion-infected
hamsters at terminal stages
To assess the potential changes of MAP2 in the brain tissues of
TSE, 10% brain homogenates of four scrapie strain 263K prion-
infected hamsters were included in this analysis. The amounts of
MAP2, tubulin and total PrP were evaluated by Western blots with
specific antibodies. Large amounts of total PrP signals were
detected in the brains of 263K prion-infected hamsters, while the
signals of MAP2, including MAP2a and 2b with Mr. 280 and
270 kDa, and MAP2c and 2d with Mr. 70 and 75 kDa, were
almost undetectable (Fig. 1A). The amounts of tubulin in the
brains of 263K-infected animals also remarkably decreased
compared to that of healthy hamsters (Fig. 1A). Relative protein
levels were normalized to b-actin control and showed that the
mean relative quantities of MAP2a/2b, MAP2c,2d and tubulin in
the brains of 263K-infected hamsters were significantly lower,
Figure 1. Comparative analyses of the levels of MAP2 in brain tissues of normal and 263K-infected hamsters. A. Western blots. Same
amounts of individual brain homogenate were loaded in 6% or 12% SDS-PAGE and various specific immunoblots were marked on the left side of the
graphs. B. Quantitative analysis of each gray numerical value of MAP2a/2b, MAP2c, 2d, tubulin and total PrP vs that of individual b-actin. The average
values were calculated from four individual infected hamsters or three individual normal hamsters and presented as mean 6 SD. Statistical
differences compared with controls were illustrated as P,0.05 or P,0.01. C. IHC assays of MAP2, total PrP and GFAP in cortex of normal and 263K-
infected hamsters. The magnifications are 620 in the left row and 640 in the right row.
doi:10.1371/journal.pone.0030163.g001
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healthy ones (P,0.05, Fig. 1B).
To verify the reduction of MAP2 in scrapie-infected animals,
the status of MAP2 in the brain tissues of 263K-infected hamsters
were analyzed with MAP2-specific immunohistochemistry (IHC).
In parallel, PrP
Sc deposits and astrogliosis were monitored with
PrP-and GFAP-specific IHC. As expected, large quantities of
PrP
Sc deposits were observed in cortex regions of 263K-infected
hamsters but not in normal controls (Fig. 1C, third row from top).
More GFAP positively stained long-fibrous like cells were detected
in the brain of 263K-infected hamsters, but there were almost no
such structures in the normal animals (Fig. 1C, second row).
MAP2 positive-stained particles were easily observable in the
brains of normal hamsters, but much weaker in that of 263K-
infected hamsters (Fig. 1C, first rows). These data indicate that the
level of MAP2 in the brains of scrapie experimental rodents is
significantly reduced at terminal stages of the disease.
Alteration of MAP2 isoforms during the incubation time
In order to investigate the dynamic changes of MAP2 isoforms
in the brains of scrapie-infected hamsters during incubation
period, the expressing level of MAP2 in the brain samples of
263K-infected hamsters collected on the 0th, 20th, 40th, 60th,
and 80th days post-inoculation (dpi) was comparatively evaluated
by Western blot. Fig. 2A revealed obvious PK-resistant PrP
signals (PrP
res) in the brains of 263K-infected hamsters since
40 dpi, but not in normal controls. The signal intensities of total
PrP and PrP
res became stronger along with the incubation
prolonging, showing a time-dependent manner. In contrast, the
signals of MAP2c,2d weakened gradually along with the
incubation and that of MAP2a/2b even vanished in the samples
of 20 dpi (Fig. 2A). After normalized to respective b-actin, the
data revealed a clear time-dependent increase of PrP and PrP
Sc
and a time-dependent decrease of MAP2 isoforms with prolong-
ing incubation (Fig. 2B).
Figure 2. Dynamic analysis of MAP2 and PrP
Sc in the brain tissues of normal and 263K-infected hamsters during incubation period.
A. Western blots. Same amounts of individual brain homogenate were loaded in 6% or 12% SDS-PAGE. Various specific immunoblots were marked on
the left and the time of post-inoculation are showed as days (d) at the bottom. B. Quantitative analysis of each gray numerical value of MAP2a/2b,
MAP2c, 2d and PrP
Sc vs that of individual b-actin. The average relative gray value is calculated from three independent blots and presented as mean
6 S.D.
doi:10.1371/journal.pone.0030163.g002
Figure 3. Analyses of the levels of MAP2 in the brain tissues of human prion diseases. A. Western blots of six brain regions of a gCJD
patient (left panel) and a FFI patient (right panel). The immunoblots for MAP2, total PrP and b-actin are indicated on the left. Various brain regions are
indicated at the top.
doi:10.1371/journal.pone.0030163.g003
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human prion diseases
Levels of MAP2 expression in postmortem brain from a G114V
gCJD patient and a D178N FFI patient were assessed by Western
blots, including frontal lobe, parietal lobe, occipital lobe, temporal
lobe, thalamus and cingulated gyrus. In line with the observations
in 263K-infected hamsters, MAP2 specific signals were barely
detectable in all tested brain regions from either G114V gCJD or
D178N FFI, but were clearly detectable in controls (Fig. 3). This
finding suggests that the reduction of MAP2 in central nervous
tissues is a common feature for TSEs.
PrP106–126 peptide induced the decline of MAP2 in the
cultured cells
The cytotoxic peptide PrP106–126 has been widely used to
mimic the pathological features of PrP
Sc in vitro. To identify the
potential influences of PrP106–126 on MAP2 levels in the
cultured cells, human neuroblastoma cells SK-N-SH were
Figure 4. Analyses of the MAP2 levels in SK-N-SH cells exposed to PrP106–126. A. SK-N-SH cells were treated with 200 mM of PrP106–126,
scrambled peptide PrP106–126 (SCR) or DMSO for 6 h and 12 h. The treated cells were photographed with a light microscope (620). B. Cell viability
after exposed to different concentrations of PrP106–126 or SCR. The average data of each preparation was calculated based on three independent
experiments and represented as mean 6 S.D. C. Western blots of MAP2a/2b, MAP2c, 2d and b-actin in SK-N-SH cells after treated with 200 mMo f
PrP106–126, SCR or DMSO for 6 h and 12 h. D. Quantitative analyses of each gray numerical value of MAP2a/2b, MAP2c, 2d vs that of individual b-
actin. The average relative gray value is calculated from three independent blots and presented as mean 6 S.D. Statistical differences compared with
controls are illustrated as P,0.05 and P,0.01.
doi:10.1371/journal.pone.0030163.g004
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exposed to DMSO (upper), PrP106–126 (middle) or SCR (lower) for 6 h. The images of MAP2 (red), DAPI (blue) and merge are indicated above.
B. Quantitative analysis of fluorescence intensity of MAP2 in the cells. MOD data each preparation is calculated from three independent images
and presented as mean 6 S.D. Statistical differences is illustrated as P,0.01.
doi:10.1371/journal.pone.0030163.g005
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PrP106–126 (SCR). Morphological assays revealed obvious
abnormality on the cells treated with 200 mM PrP106–126 for
12 h (Fig. 4A). Cell viability tests also identified markedly
cytotoxicity in the preparations exposed to 200 mM PrP106–
126, while the cells exposed to SCR peptide remained almost
unchanged (Fig. 4B). Western blots of the cell lysates showed that
the levels of MAP2 in cells treated with PrP106–126 for 6 and
12 h were significantly reduced compared to the control groups
(DMSO and SCR) (Fig. 4C). Analyse of the relative gray values of
each blot after normalization with b-actin revealed a statistically
significant decrease of isoforms in PrP106–126 treated cells
(Fig. 4D).
The finding that PrP106–126 reduces cellular MAP2 levels was
further verified by immunofluorescence staining. Cells exposed to
PrP106–126, SCR peptide and DMSO for 6 h were subjected into
immunofluorescent assays with anti-MAP2 antibody. PrP106–126
treatment led to weaker MAP2 stained signals (red color) in the
cytoplasm of the cells compared with SCR peptide or DMSO
treatment. (Fig. 5A). Comparison of the MOD values among the
three preparations showed significant difference (P,0.01) between
the groups of PrP106–126 and DMSO, or between PrP106–126
and SCR peptide (Fig. 5B). These data imply that the treatment of
PrP106–126 induces an obvious reduction of MAP2 in the
cultured cells.
Treatment of PrP106–126 on SK-N-SH cells did not alter
the level of cellular tubulin but destroyed cellular
cytoskelet al network
To detect the effects of PrP106–126 on cellular tubulin and
microtubule, SK-N-SH cells were treated with 200 mM PrP106–
126 or SCR peptide. Our result showed there is no significant
changes in the expression levels of cellular tubulin after exposure
to PrP106–126 for 6 or 12 hours(Fig. 6A and B). Immunofluo-
rescence staining with an anti-tubulin antibody was performed on
cells exposed to various agents were to visualize the alteration of
cytoskeletal network. In the cells treated with DMSO and SCR
peptide, large amounts of long fibril-like microtubule structures
were observed in the cytoplasm. In cells exposed to PrP106–126,
the fibril-like structures disappeared and only variably sized
granular elements were observed (Fig. 6C). These results suggest
that, under our experimental condition, cytotoxic peptide PrP106–
126 induces a rapid disorganization of cellular microtubule
network before significantly reducing tubulin levels.
Increase of calpain in PrP106–126 treated cells
Calpain is believed to cause degradation for a series of cell
cytoskeletal proteins. To gain insight into the possible relationship
between MAP2 and calpain, the level of calpain in the SK-N-SH
cells treated with PrP106–126 was evaluated by Western blots.
Figure 6. Analyses of the tubulin levels and microtubule structure in cells exposed to DMSO, PrP106–126 or SCR. A. Western blots
with anti-a-tubulin mAb. B. Quantitative analyses of each gray numerical value of tubulin vs that of individual b-actin. The average relative gray value
is calculated from three independent blots and presented as mean 6 S.D. C. Immunofluorescence images of cellular microtubule structure.
doi:10.1371/journal.pone.0030163.g006
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exposed to PrP106–126 (Fig. 7A), showing a significant increase
(P,0.01) compared to cells treated with SCR peptide and DMSO
(Fig. 7B). To detect the influence of inhibition by calpain on the
MAP2 levels, calpain inhibitor ALLN was introduced into the cells
exposed to PrP106–126. Compared with the remarkable reduction
of MAP2a/2b in the cells exposed to PrP106–126, the cellular
MAP2a/2b levels in cells exposed to PrP106–126 plus ALLN were
almost as high as that of control of DMSO cells (Fig. 7C and D).
ALLN treatment alone did not affect the level of MAP2 or calpain
(data not shown). These data highlight that exposure of the
cytotoxic peptide PrP106–126 to the cultured cells induces an
increased calpain level, whcih might be responsible for the
reduction of MAP2.
Increase of calpain in the brains of 263K-infected
hamsters
We also tested the potential alterations of calpain in the brain
tissues of TSE experimental animals. The protein level of calpain
was much higher in 263K-infected hamsters than normal controls
(Fig. 8A) and quantification revealed a significant difference
(P,0.01) between two groups (Fig. 8B). To determine the
dynamic changes of calpain during prion infection, levels of
calpain in the brains of 263K-infected hamsters collected during
incubation period were comparatively analyzed by Western blot.
An obvious time-dependent increase of calpain was observed
along with the prolonging incubation, accompanying with a
gradually decrease of tubulin signals (Fig. 8C and D). These data
indicates a more active status of calpain in the brain tissues of
TSE infected animals.
Inhibition of calpain activity reversed the PrP106–126
induced destruction on microtubule structure and
cytotoxicity
To evaluate potential role of calpain in mediating the PrP106–
126-induced destruction of microtubule structures network and
cytotoxicity, SK-N-SH cells were pretreated with 20 mM ALLN
for 4 h and then cells were exposed to PrP106–126 for 12 h. As
expected, cellular microtubule was significantly impaired when
cells were treated with PrP106–126. Importantly, the destructive
effects of PrP106–126 was substantially reversed in the cells
pretreated with ALLN. ALLN alone did not change the cellular
microtubule structure (Fig. 9A). Morphological analyses revealed
more normal cells after the treatment of PrP106–126 plus ALLN
than that of PrP106–126 alone (Fig. 9A). CCK8 tests identified
that the cell viability of the reaction of PrP106–126 plus ALLN
was partially, but significantly (P,0.05) improved compared with
that of PrP106–126 (Fig. 9B). This result suggests that inhibition of
calpain activity is able to partially reverse PrP106–126 induced
cytotoxicity.
Discussion
In this study we have demonstrated that levels of MAP2 in the
CNS tissues of a scrapie experimental rodent model and in the
postmortem brains of the patients of genetic prion diseases are
significantly reduced, highlighting a common phenotype in TSEs.
Mammalian brain MAP2 is composed of at least four isoforms,
designated as MAP2a, 2b, 2c, and 2d, varying from the
electrophoresis mobility on SDS-PAGE. Through alternative
splicing of a pre-mRNA transcribed from a single gene located
Figure 7. Analyses of calpain levels in PrP106–126 treated SK-N-SH cells. A. Western blots of calpain in cells exposed to DMSO, PrP106–126
or SCR. B. Quantitative analyses of the gray numerical values of calpain. The average relative gray value is calculated from three independent blots
and presented as mean 6 S.D. Statistical differences are illustrated as P,0.01. C. Western blots of MAP2 in the cells treated with PrP106–126 alone
and PrP106–126 plus calpain inhibitor ALLN. D. Quantitative analyses of the gray numerical values of MAP2a/2b, MAP2d and MAP2c. The average
relative gray value is calculated from three independent blots and presented as mean 6 S.D. Statistical differences are illustrated as P,0.01.
doi:10.1371/journal.pone.0030163.g007
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translated and presented in the CNS tissues [22]. In line with
the observations that MAP2a/2b are the most abundant forms in
adult brains [23,24], clear MAP2a/2b bands are detected in the
brain tissues of adult hamsters and human. Meanwhile, weak
MAP2c/2d bands in the brain lysates of adult hamsters are
consistent with that LMWMAP2 are mainly expressed during
early developmental stages, which may decrease dramatically in
the brains of mice postnatal 20 days [25].
Earlier studies have found that MAP2 polyclonal antibody
might label abnormal neurites around senile plaques [26], and
accumulation of soluble Ab oligomers in a transgenic mouse
model of AD results in a decrease in MAP2 labeling before these
mice develop plaques [12], suggesting a possible role of MAP2 in
neurodegenerative diseases. As a biomarker for neurons, reduction
of MAP2 at the terminal stages of TSEs is reasonable. However,
compared with the alteration of another neuronal marker NSE
that reduces but usually remains detectable in prion diseases with
conventional techniques (such as Western blot and IHC), the
reduction of MAP2 isoforms are much significant and almost no
specific signal could be detected by Western blots. In addition, our
dynamic analysis of scrapie-infected rodents identify that the
disappearance of MAP2 seems to occur at the early stage of
infection, as it reduces to undetectable level in the 20 dpi samples.
At this time, pathological PrP
Sc start to deposit in CNS tissues,
which are visible in the assays of immunohistochemistry, but
undetectable by Western blots [27]. Springer and his co-workers
have proposed that MAP2 decreased dramatically within 1 hour
after traumatic spinal cord injury, which is believed that as
somatodendritic compartments of neurons, MAP2 may be
especially vulnerable during diseases of nervous system [28].
Although we do not know the exact time when MAP2 starts to
drop-down during prion infection, our data here indicate that the
expression of MAP2 in neurons is more vulnerable during the
progression of prion diseases, which may reflect that both the
biological function of MAP2 in neurons and the cluster of MAP2
positive neurons are affected. Moreover, the reduction of MAP2
isoforms has been reproduced in a cultured neuroblastoma cell
line exposed to the cytotoxic peptide PrP106–126 in this study. It
emphasizes again the possibility of the disruption of MAP2
exposed to pathological prion.
Previous reports have suggested that PrP106–126 can bind to
microtubules [29] and electron microscopy has confirmed that
PrP106–126 can enter the cytosol and bind to microtubules when
applied to cultured cerebellar cells [30]. PrP106–126 also shows
the ability to inhibit tubulin polymerization by preventing the
Figure 8. Analyses of calpain levels in the brain tissues of 263K-infected hamsters. A. Western blots of calpain in the infected and normal
hamsters. B. Quantitative analyses of the gray numerical values of calpain. The average gray values were calculated from four infected hamsters or or
four normal after normalized with that of individual b-actin and presented as mean 6 SD. Statistical difference is illustrated as P,0.01. C. Western
blots of calpain and tubulin in the brain tissues of 263K-infected hamsters on 0, 20, 40, 60 and 80 dpi. D. Quantitative analyses of the gray numerical
values of calpain and tubulin vs that of individual b-actin. The average relative gray value is calculated from three independent blots and presented as
mean 6 S.D.
doi:10.1371/journal.pone.0030163.g008
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interacting partner, the polymerization of tubulin and the cellular
microtubule structures can be impaired directly via interacting
with a couple of CJD-associated PrP mutants [16,18], or indirectly
via influencing on other microtubule associated proteins, such as
tau [32] and TPPP [33]. Tubulin level has also been proved to be
decreased in the brains of different TSEs [16]. These data strongly
indicate that the disruption of microtubule structure is one of
milestones in the pathogenesis of prion disease. As an important
component of MAPs, it is reasonable to hypothesize that the
reduction of MAP2 will be another pathway to demolish
microtubule structures in TSEs. Additionally, our data here
illustrate that the reduction of MAP2 and disruption of
microtubule structure occur earlier and more obvious than the
changes of tubulin and deposits of PrP
Sc, highlighting that change
of MAP2 is an early and persistent event in progression of TSEs.
Figure 9. Inhibition of calpain activity reversed the PrP106–126-induced destruction on microtubule structures and cytotoxicity.
A. SK-N-SH cells were treated with 200 mM of PrP 106–126 with or without calpain inhibitor ALLN for 12 h. Immunofluorescence images of cellular
microtubule structure (upper) and morphological analyses of cells (lower) were shown. B. Cell viability after exposed to PrP106–126 with or without
ALLN. The average data of each preparation was calculated based on three independent experiments and represented as mean 6 S.D. Statistical
differences are illustrated as P,0.05.
doi:10.1371/journal.pone.0030163.g009
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neurons, interference with microtubule network is likely to lead to
apoptosis with the impairment of axonal transport of various
vesicles and organelles [34].
Calpain is a ubiquitous calcium-dependent protease which is
essential for physiological neuronal function and the activation of
calpain can be triggered by calcium influx and oxidative stress
[35]. MAP2 isoforms are the substrates for the activated calpain
[13] and the neuronal apoptotic events involved in alterations of
the microtubule network are consequent to calpain activation [36].
Calpain-dependent degradation of MAP2 is known as an early
response to traumatic [28], focal ischemic brain injuries [37] and
glutamate excitotoxicity [38]. In addition, there are considerable
evidences that an increased activity of calpain associated with
impaired calcium homeostasis may be involved in AD develop-
ment [13,39,40]. Recent study has suggested that the apoptosis
induced by the peptide PrP106–126 is possibly through two
biochemical pathways, caspase and calpain [41]. Moreover, our
assays illustrate a time-dependent increase in calpain level during
scrapie infection, along with a gradually decrease in tubulin level.
Inhibition of calpain activity not only reverses the reduction of
cellular MAP2 level, but also partially rescues PrP106–126
induced cytotoxicity. It is reasonable to speculate that the abrupt
reduction of MAP2 in brain tissues is associated with the rapid
increase of calpain in prion diseases. Actually, disturbance of the
calpain system in CNS tissues has been observed in some
neurodegenerative diseases including Alzheimer’s [42], Parkin-
son’s [43] and prion diseases [41]. The central role of microtubules
and microtubule transport even make them an appealing target in
developing therapy of neurodegenerative diseases. Neuronal death
due to PrP106–126 is reduced following pharmacologic calpain
inhibition [39] and MAP2 degradation is reversed by pretreated
with calpain inhibitor in neuronal cells exposed to Ab [13]. Hence,
further characterizations of the role of calpain and MAP2 in the
pathogenesis of prion diseases are specially needed.
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